Investor Presentation First Nine Months of 2022
8
Investor presentation First nine months of 2022
Novo NordiskⓇ
GLP-1 class expansion continues in the US as new prescriptions
have accelerated in the third quarter of 2022
US GLP-1 weekly NBRx prescriptions
Weekly NBRX
scripts ('000s)
50
50
40
40
30
20
10
0
Oct
2020
Ozempic Rybelsus®
US GLP-1 TRX market share
Total GLP-1 scripts
TRX share
(millions)
60%
Class growth >40%
49.0%
4
52.4%
40%
20%
0%
Oct
Oct
2022
2020
VictozaⓇ
NN GLP-1
dulaglutide tirzepatide
3
38.7%
35.8%
2
10.3%
1
7.3%
6.4%
0
Oct
2022
Total monthly GLP-1 scripts
Source: IQVIA Xponent, Weekly (ending 14 Oct 2022) Each data points represents a rolling four-week average. Total GLP-1 scripts constitute all prescriptions of GLP-1 medications in the market and have the full month of September as latest available data point
NBRX: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions
Note: Class growth calculated as Q3 2022 vs Q3 2021View entire presentation